HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA’s Stance On CBD In Cosmetics Hasn’t Changed, And Neither Have Marketing Challenges

Executive Summary

The FDA continues working to close cannabidiol data gaps while maintaining that CBD-containing cosmetics cannot be adulterated, misbranded or marketed as affecting body structure/function or treating or preventing disease, including skin ailments. Cosmetics office head Linda Katz revisited the issue during the Independent Beauty Association’s annual FDA Cosmetics Regulations Workshop.

You may also be interested in...



CIR Expert Panel To Prioritize Cannabidiol Review In 2024 At FDA’s Request

Cosmetic Ingredient Review’s independent experts note that CBD use in cosmetic products has increased since FDA first asked them to prioritize its review in 2020.

US FDA Support For Cosmetic Allergen Labeling Has Foundation In Consumers' ‘Right To Know’

Office of Cosmetics and Colors Linda Katz emphasizes FDA sees allergen labeling as a public health issue. While many allergic reactions are minor, “consumers who are extremely or exclusively sensitive to a particular ingredient should have a right to know.”

US FDA’s Cosmetics Director Katz Cites Fragrance Allergens, Talc-Containing Products Among Priorities

Linda Katz, director of the US FDA’s Office of Cosmetics and Colors, offered insight into priority cosmetics issues at the Independent Beauty Association’s virtual FDA Cosmetic Regulations Workshop.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel